Vascular Perfusion Solutions, Inc., a pioneering Texas-based early-stage Medtech company, is thrilled to announce that it has successfully raised $4,000,000 in its latest funding round. This significant capital infusion reinforces the company’s commitment to transforming the landscape of organ transplantation through innovative technology. At the heart of this mission is the VP.S ENCORE®, a state-of-the-art hypothermic machine perfusion device that redefines prolonged cardiac graft preservation. This breakthrough product not only offers simplicity, ease of use, and accessibility but also delivers enhanced performance when compared with conventional ice-cooler preservation methods. Since receiving FDA breakthrough device designation in 2021, the VP.S ENCORE® has undergone successful preclinical testing, including studies on over 100 hearts from ovine, porcine, and human donors, underscoring its potential to significantly improve transplant outcomes.
The newly raised funds will be strategically allocated to further advancing the product’s development and to scaling its production capabilities, ensuring that the technology can meet growing demand in both domestic and international markets. By accelerating progress toward broader regulatory approvals and market penetration, the company aims to set new benchmarks in cardiac preservation technology and to expand access to lifesaving treatments across the organ transplant community. This funding milestone marks an important step in VPS’s journey to not only innovate but also to democratize advanced medical solutions that have the potential to save countless lives. As VPS continues to push the boundaries of Medtech innovation, the future of organ preservation—and the future of transplantation—looks brighter than ever.
